The results of a recent phase 2 study to evaluate the safety and efficacy of anlotinib for the first-line treatment of metastatic renal cell carcinoma (RCC) were published in The Oncologist this month. Anlotinib was developed in China, and is a new tyrosine kinase inhibitor inhibiting multiple kinases involved in the growth of new blood vessels (angiogenesis) and tumour proliferation.

The results showed that anlotinib has comparable efficacy to sunitinib for the treatment of metastatic RCC; however, anlotinib has a more favourable safety profile than that of sunitinib.

Read more in UroToday here